DYN
Dyne Therapeutics Inc
NASDAQ: DYN · HEALTHCARE · BIOTECHNOLOGY
$17.41
-4.13% today
Updated 2026-04-29
Market cap
$2.88B
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-3.47
Dividend yield
—
52W range
$8 – $25
Volume
2.2M
Dyne Therapeutics Inc (DYN) Financial statements
SEC filings — annual and quarterly data.
Profit margin
0.00%
Operating margin
0.00%
ROE
-55.70%
ROA
-31.20%
Debt/equity
—
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2007 | $3.10B | $264.00M | 35.13% | 19.50% | 8.51% |
| 2008 | $3.55B | $174.00M | 47.79% | 19.98% | 4.90% |
| 2009 | $2.47B | $-1.26B | 51.62% | -33.79% | -51.13% |
| 2010 | $2.32B | $-234.00M | 49.16% | -0.47% | -10.07% |
| 2011 | $1.58B | $-1.65B | 39.24% | -14.89% | -103.79% |
| 2012 | $3.00M | $87.00M | -8,833.33% | 23,800.00% | 2,900.00% |
| 2013 | $3.00M | $-356.00M | -38,066.67% | -10,600.00% | -11,866.67% |
| 2014 | $1.47B | $-67.00M | 21.90% | -21.69% | -4.57% |
| 2015 | $842.00M | $50.00M | -140.86% | 7.60% | 5.94% |
| 2016 | $1.37B | $-1.24B | -66.98% | -46.85% | -90.78% |
| 2017 | $506.00M | $76.00M | -479.45% | -81.42% | 15.02% |
| 2018 | $0.00 | $-4.81M | — | — | — |
| 2019 | $0.00 | $-13.54M | — | — | — |
| 2020 | $0.00 | $-58.74M | — | — | — |
| 2021 | $0.00 | $-149.29M | — | — | — |
| 2022 | $0.00 | $-165.24M | — | — | — |
| 2023 | $0.00 | $-235.94M | — | — | — |
| 2024 | $0.00 | $-317.42M | — | — | — |
| 2025 | $0.00 | $-446.21M | — | — | — |